Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma

Archives of Dermatology

Volumn 145, Issue 1, 2009, Pages 98-99

  Vallés, Lara ^b   González, Marta ^b   Polo, Isabel ^b   Enguita, Ana B ^b   Vanaclocha, Francisco ^b   Ortiz Romero, Pablo L ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; CANCER IMMUNOTHERAPY; CASE REPORT; FEMALE; HUMAN; HUMAN TISSUE; INJECTION SITE REACTION; LETTER; LIPOATROPHY; MELANOMA; PRIORITY JOURNAL; SKIN BIOPSY; URTICARIA;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; LIPODYSTROPHY; MELANOMA; SKIN NEOPLASMS; THIGH; YOUNG ADULT;

EID: 58849140420     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2008.531     Document Type: Letter

References (4)

1. Guillot B, Blazquez L, Bessis D, Dereure O, Guilhou JJ. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma. Dermatology. 2004;208(1):49-54.
2. Sparsa A, Loustaud-Ratti V, Liozon E, Denes E, Soria P, Bouyssou-Gauthier ML. Cutaneous reactions or necrosis from interferon alpha: can interferon be reintroduced after healing? six case reports. Rev Med Interne. 2000;21(9):756-763.
3. Beiske AG, Myhr KM. Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis. J Neurol. 2006;253(3):377-378.
4. Christeff N, Melchior J-C, Truchis P, Perronne C, Gougeon M-L. Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome. Eur J Clin Invest. 2002;32(1):43-50.